Annual report
9158.TEDINET S100TWCD
Period2023-04-01 → 2024-03-31
Filed2024-06-27
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 132
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.0bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥35.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥35.3bn | 2021-04-01 → 2022-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥16.6bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥3.7bn | 2023-04-01 → 2024-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥3.7bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥3.6bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥1.6bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥2.7bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥1.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥62.8bn | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥39.8bn | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥34.5bn | at 2022-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥28.4bn | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥34.8bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥27.8bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥28.0bn | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥11.9bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥9.7bn | at 2022-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥27.3bn | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥11.7bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥9.5bn | at 2022-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥4.7bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥8.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.1bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥4.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥3.6bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥4.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥2.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥6.6bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥2.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥14.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥6.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥1.5bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥2.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | ¥14.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥4.0bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥4.4bn | 2021-04-01 → 2022-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥591m | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥93.99 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥113.9 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥52.71 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥93.99 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥113.9 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥129.68 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥52.71 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥931.79 | at 2024-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥533.1 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥453.12 | at 2022-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥226.83 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 43.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 29.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 27.4% | at 2022-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 16.6% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 13.3% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 22.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 38.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 27.1% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 3,743 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 2,994 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 2,470 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,819 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥7.8bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥14.3bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥15.4bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥4.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.9bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.4bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥795m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥312m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.9bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥1.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥574m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥122m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥45.5bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥28.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥23.9bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥19.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥18.6bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥23.2bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥20.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥22.3bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥8.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥7.4bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥3.9bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.3bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥3.4bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥554m | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥46.01 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.21 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.53 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.98 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥1,145.5 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥759.3 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥365.69 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥335.57 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥176.49 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥30,101.95 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 48.8% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.9% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 30.6% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 29,990,400 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 113,152 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,352 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 434 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 423 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 374 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 304 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 310 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 55
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 5 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥18m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥696m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥696m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥1.2bn |
| Hospicereportable segment | employees | at 2024-03-31 | 1391 pure |
| Hospicereportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.4bn |
| Hospicereportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.4bn |
| Hospicereportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| Hospicereportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥349m |
| In Home Nursingreportable segment | employees | at 2024-03-31 | 1455 pure |
| In Home Nursingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.9bn |
| In Home Nursingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.9bn |
| In Home Nursingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥0 |
| In Home Nursingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥616m |
| Medical Institutionreportable segment | employees | at 2024-03-31 | 808 pure |
| Medical Institutionreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥12.2bn |
| Medical Institutionreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.5bn |
| Medical Institutionreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥695m |
| Medical Institutionreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥3.9bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥33.5bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥32.8bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥696m |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥33.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥33.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥696m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥4.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥205m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥29m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥263m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥263m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥843m |
| Hospicereportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Hospicereportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥6.6bn |
| Hospicereportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥191m |
| In Home Nursingreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥12.2bn |
| In Home Nursingreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥12.2bn |
| In Home Nursingreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Medical Institutionreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥16.4bn |
| Medical Institutionreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥16.2bn |
| Medical Institutionreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥263m |
| Medical Institutionreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥35.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥35.0bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥263m |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥35.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥35.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥263m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥4.5bn |
| Medical Institutionreportable segment | employees | at 2024-03-31 | 350 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,678
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentYearInstant | 28005000000 | JPY |
| Liabilities and equity IFRS | Prior1YearInstant | 39750000000 | JPY |
| Liabilities and equity IFRS | CurrentYearInstant | 62836000000 | JPY |
| Revenue IFRS | Prior1YearDuration | 35210000000 | JPY |
| Revenue IFRS | CurrentYearDuration | 33025000000 | JPY |
| Cost of sales IFRS | Prior1YearDuration | 21434000000 | JPY |
| Cost of sales IFRS | CurrentYearDuration | 17102000000 | JPY |
| Gross profit IFRS | Prior1YearDuration | 13776000000 | JPY |
| Gross profit IFRS | CurrentYearDuration | 15923000000 | JPY |
| Selling general and administrative expenses IFRS | Prior1YearDuration | 10015000000 | JPY |
| Selling general and administrative expenses IFRS | CurrentYearDuration | 12206000000 | JPY |
| Other income IFRS | Prior1YearDuration | 45000000 | JPY |
| Other income IFRS | CurrentYearDuration | 64000000 | JPY |
| Other expenses IFRS | Prior1YearDuration | 123000000 | JPY |
| Other expenses IFRS | CurrentYearDuration | 45000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 3683000000 | JPY |
| Operating profit loss IFRS | CurrentYearDuration | 3737000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 50000000 | JPY |
| Finance income IFRS | CurrentYearDuration | 687000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 99000000 | JPY |
| Finance costs IFRS | CurrentYearDuration | 285000000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 3634000000 | JPY |
| Profit loss before tax IFRS | CurrentYearDuration | 4138000000 | JPY |
| Income tax expense IFRS | Prior1YearDuration | 1230000000 | JPY |
| Income tax expense IFRS | CurrentYearDuration | 1531000000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 2404000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 2608000000 | JPY |
| Profit loss attributable to owners of parent IFRS | Prior1YearDuration | 2423000000 | JPY |
| Profit loss attributable to owners of parent IFRS | CurrentYearDuration | 2595000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | Prior1YearDuration | -19000000 | JPY |
| Profit loss attributable to non controlling interests IFRS | CurrentYearDuration | 12000000 | JPY |
| Profit loss IFRS | Prior1YearDuration | 2404000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 2608000000 | JPY |
| Basic earnings loss per share IFRS | Prior1YearDuration | 113.90 | |
| Basic earnings loss per share IFRS | CurrentYearDuration | 93.99 | |
| Diluted earnings loss per share IFRS | Prior1YearDuration | 113.90 | |
| Diluted earnings loss per share IFRS | CurrentYearDuration | 93.99 | |
| Profit loss IFRS | Prior1YearDuration | 2404000000 | JPY |
| Profit loss IFRS | CurrentYearDuration | 2608000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | -581000000 | JPY |
| Net change in fair value of equity instruments designated as measured at fair value through other comprehensive income net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -244000000 | JPY |
| Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | 2000000 | JPY |
| Remeasurements of defined benefit plans net of tax items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -5000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | Prior1YearDuration | -579000000 | JPY |
| Total of items that will not be reclassified to profit or loss oci IFRS | CurrentYearDuration | -249000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | Prior1YearDuration | 134000000 | JPY |
| Exchange differences on translation of foreign operations net of tax items that may be reclassified to profit or loss oci IFRS | CurrentYearDuration | 177000000 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | Prior1YearDuration | 134000000 | JPY |
| Total of items that may be reclassified to profit or loss oci IFRS | CurrentYearDuration | 177000000 | JPY |
| Other comprehensive income IFRS | Prior1YearDuration | -445000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |